184 related articles for article (PubMed ID: 28668589)
1. Rare splicing defects of FAS underly severe recessive autoimmune lymphoproliferative syndrome.
Agrebi N; Ben-Mustapha I; Matoussi N; Dhouib N; Ben-Ali M; Mekki N; Ben-Ahmed M; Larguèche B; Ben Becher S; Béjaoui M; Barbouche MR
Clin Immunol; 2017 Oct; 183():17-23. PubMed ID: 28668589
[TBL] [Abstract][Full Text] [Related]
2. Novel insights into FAS defects underlying autoimmune lymphoproliferative syndrome revealed by studies in consanguineous patients.
Ben-Mustapha I; Agrebi N; Barbouche MR
J Leukoc Biol; 2018 Mar; 103(3):501-508. PubMed ID: 29345341
[TBL] [Abstract][Full Text] [Related]
3. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease?
van der Burg M; de Groot R; Comans-Bitter WM; den Hollander JC; Hooijkaas H; Neijens HJ; Berger RM; Oranje AP; Langerak AW; van Dongen JJ
Pediatr Res; 2000 Mar; 47(3):336-43. PubMed ID: 10709732
[TBL] [Abstract][Full Text] [Related]
6. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.
Neven B; Magerus-Chatinet A; Florkin B; Gobert D; Lambotte O; De Somer L; Lanzarotti N; Stolzenberg MC; Bader-Meunier B; Aladjidi N; Chantrain C; Bertrand Y; Jeziorski E; Leverger G; Michel G; Suarez F; Oksenhendler E; Hermine O; Blanche S; Picard C; Fischer A; Rieux-Laucat F
Blood; 2011 Nov; 118(18):4798-807. PubMed ID: 21885602
[TBL] [Abstract][Full Text] [Related]
7. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
8. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
9. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
11. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
12. Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome.
Pellé O; Moreno S; Lorenz MR; Riller Q; Fuehrer M; Stolzenberg MC; Maccari ME; Lenoir C; Cheminant M; Hinze T; Hebart HF; König C; Schvartz A; Schmitt Y; Vinit A; Henry E; Touzart A; Villarese P; Isnard P; Neveux N; Landman-Parker J; Picard C; Fouyssac F; Neven B; Grimbacher B; Speckmann C; Fischer A; Latour S; Schwarz K; Ehl S; Rieux-Laucat F; Rensing-Ehl A; Magérus A
J Allergy Clin Immunol; 2024 Jan; 153(1):203-215. PubMed ID: 37793571
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS).
Lisco A; Wong CS; Price S; Ye P; Niemela J; Anderson M; Richards E; Manion M; Mystakelis H; Similuk M; Lo B; Stoddard J; Rosenzweig S; Vanpouille C; Rupert A; Maric I; Perez-Diez A; Parenti D; Burbelo PD; Rao VK; Sereti I
Front Immunol; 2019; 10():1193. PubMed ID: 31191551
[TBL] [Abstract][Full Text] [Related]
15. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
18. Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.
Hafezi N; Zaki-Dizaji M; Nirouei M; Asadi G; Sharifinejad N; Jamee M; Erfan Rasouli S; Hamedifar H; Sabzevari A; Chavoshzadeh Z; Yazdani R; Abolhassani H; Aghamohammadi A; Azizi G
Pediatr Allergy Immunol; 2021 Oct; 32(7):1519-1532. PubMed ID: 33963613
[TBL] [Abstract][Full Text] [Related]
19. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
20. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
